---
title: "PD-1 Chimeric Switch Receptor T Cells Improve Tumor Selectivity of PD-L1 Targeting"
id: "biorxiv-3-a-standalone-pd-1-chimeric-switch-receptor-t-cell-platform-expands-the"
canonical_url: "https://medichelpline.com/clinical-feed/biorxiv-3-a-standalone-pd-1-chimeric-switch-receptor-t-cell-platform-expands-the"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "bioRxiv (Biomedical Preprints)"
source_url: "https://www.biorxiv.org/content/10.64898/2026.11.05.764663v1?rss=1"
published_at: "2026-11-09T11:26:10.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# PD-1 Chimeric Switch Receptor T Cells Improve Tumor Selectivity of PD-L1 Targeting
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/biorxiv-3-a-standalone-pd-1-chimeric-switch-receptor-t-cell-platform-expands-the
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** bioRxiv (Biomedical Preprints)
- **Source URL:** [Original Journal Publication](https://www.biorxiv.org/content/10.64898/2026.11.05.764663v1?rss=1)
- **Published At:** 2026-11-09T11:26:10.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Researchers developed a standalone **PD-1 chimeric switch receptor (CSR)** T-cell platform to target **PD-L1** on tumors and immunosuppressive myeloid cells while reducing normal-tissue reactivity. - Iterative receptor engineering was used with parallel selection for antitumor potency and reduced normal-cell cytotoxicity. - Two lead PD-1 CSR T-cell candidates emerged from the selection process based on those dual criteria. - The lead candidates retained potent PD-L1–specific cytotoxicity against tumor cells while showing markedly reduced killing of primary human small airway epithelial cells, astrocytes, renal epithelial cells, hepatocytes, and cardiomyocytes. - Investigators reported efficient elimination of PD-L1–positive immunosuppressive myeloid cells and demonstrated dual-compartment activity in three-dimensional multicellular tumor organoids. - In vivo, both candidates suppressed tumor growth and extended survival in orthotopic breast cancer and patient-derived glioblastoma models after systemic and intracranial administration, respectively. - The authors position PD-1 CSR T cells as a standalone therapeutic platform that expands the therapeutic window for PD-L1–targeted cellular therapy. - The source did not report clinical dosing, safety data in humans, or regulatory status; authors noted inventors on a provisional patent application related to the technology. - Funding sources included the National Institute of Neurological Disorders and Stroke, Florida Health Grant, Florida State Casey DeSantis Cancer Research Funding, Florida Cancer Innovation Fund, and the Georg Haub Family Career Development Award.
## Clinical Analysis & Structured Key Points
[](https://www.biorxiv.org/cdn-cgi/content?id=zOt61ppNcu2TBt00cPmkp6BRdda6ae8bfzK9tEE2OCU-1794223601.502864-1.2.1.1-Mk54UlmGM1LnYiiSt68NfD7kh5Q0.bF9zpkJ9XcaZhcKQPa0WfZyTvJbPqut.VGL) [Skip to main content](https://www.biorxiv.org/content/10.64898/2026.11.05.764663v1?rss=1#main-content) [![bioRxiv](https://www.biorxiv.org/sites/default/files/biorxiv_article_logo.jpg)](https://www.biorxiv.org/) * [Home](https://www.biorxiv.org/) * [Submit](https://www.biorxiv.org/submit-a-manuscript) * [FAQ](https://www.biorxiv.org/about/FAQ) * [Blog](https://connect.biorxiv.org/news/) * [ALERTS / RSS](https://www.biorxiv.org/content/alertsrss) * [Resources](https://connect.biorxiv.org/resources/) * [About](https://www.biorxiv.org/content/about-biorxiv) * [Channels](https://www.biorxiv.org/content/10.64898/2026.11.05.764663v1?rss=1) * [4D Nucleome](https://connect.biorxiv.org/relate/content/66) * [Academia Sinica](https://connect.biorxiv.org/group/content/38) * [Advances in Genome Biology and Technology (AGBT) General Meeting 2016 #AGBT16](https://connect.biorxiv.org/relate/content/10) * [Albert Einstein College of Medicine](https://connect.biorxiv.org/group/content/4) * [Aligning Science Across Parkinson's (ASAP)](https://connect.biorxiv.org/relate/content/195) * [Allen Institute for Cell Science](https://connect.biorxiv.org/relate/content/71) * [Arc Institute](https://connect.biorxiv.org/relate/content/224) * [Babraham Institute](https://connect.biorxiv.org/relate/content/197) * [BICCN/BICAN](https://connect.biorxiv.org/relate/content/208) * [BioImaging North America](https://connect.biorxiv.org/relate/content/194) * [Biology of Genomes 2016 #BOG16](https://connect.biorxiv.org/relate/content/19) * [Breakthrough Discoveries for Thriving with Bipolar Disorder](https://connect.biorxiv.org/relate/content/236) * [Brown University](https://connect.biorxiv.org/group/content/9) * [California Institute of Technology](https://connect.biorxiv.org/group/content/32) * [Carnegie Mellon University](https://connect.biorxiv.org/group/content/19) * [Case Western Reserve University](https://connect.biorxiv.org/group/content/36) * [Central Oxford Structural Microscopy and Imaging](https://connect.biorxiv.org/relate/content/143) * [Centre for Microbiology and Environmental Systems Science](https://connect.biorxiv.org/relate/content/190) * [Chan Zuckerberg Biohub](https://connect.biorxiv.org/relate/content/121) * [Columbia University](https://connect.biorxiv.org/group/content/27) * [Donders Institute for Brain, Cognition and Behaviour](https://connect.biorxiv.org/relate/content/184) * [DREAM](https://connect.biorxiv.org/relate/content/153) * [Drug Development and Clinical Therapeutics](https://connect.biorxiv.org/relate/content/52) * [ENCODE](https://connect.biorxiv.org/relate/content/177) * [Ernst Strüngmann Institute (ESI) for Neuroscience](https://connect.biorxiv.org/relate/content/211) * [European Molecular Biology Laboratory (EMBL)](https://connect.biorxiv.org/relate/content/159) * [Francis Crick Institute](https://connect.biorxiv.org/relate/content/88) * [Fred Hutchinson Cancer Center](https://connect.biorxiv.org/group/content/28) * [Georgia Institute of Technology](https://connect.biorxiv.org/group/content/20) * [Harvard Program in Therapeutic Sciences](https://connect.biorxiv.org/relate/content/151) * [The Howard Hughes Medical Institute (HHMI)](https://connect.biorxiv.org/relate/content/227) * [Human Cell Atlas](https://connect.biorxiv.org/relate/content/163) * [Human Pangenome Reference Consortium (HPRC)](https://connect.biorxiv.org/relate/content/215) * [IMO Workshop](https://connect.biorxiv.org/relate/content/8) * [Impact of Genomic Variation on Function (IGVF)](https://connect.biorxiv.org/relate/content/214) * [Institut Pasteur](https://connect.biorxiv.org/relate/content/235/channel) * [Institute of Science and Technology Austria](https://connect.biorxiv.org/group/content/12) * [International Human Epigenome Consortium (IHEC)](https://connect.biorxiv.org/relate/content/219) * [International Mouse Phenotyping Consortium (IMPC)](https://connect.biorxiv.org/relate/content/185) * [Iowa State University](https://connect.biorxiv.org/group/content/6) * [Johns Hopkins University](https://connect.biorxiv.org/group/content/47) * [Mathematical Oncology](https://connect.biorxiv.org/relate/content/1) * [Micron Oxford](https://connect.biorxiv.org/relate/content/116) * [Michigan State University](https://connect.biorxiv.org/group/content/7) * [Morgridge Institute](https://connect.biorxiv.org/group/content/57) * [National Taiwan University](https://connect.biorxiv.org/group/content/39) * [NCI Cancer Systems Biology Consortium](https://connect.biorxiv.org/relate/content/210) * [NF Open Science Initiative](https://connect.biorxiv.org/relate/content/213) * [NCI Human Tumor Atlas Network](https://connect.biorxiv.org/relate/content/171) * [Neuromatch Conference](https://connect.biorxiv.org/relate/content/209) * [NeurotechEU](https://connect.biorxiv.org/relate/content/189) * [North Carolina State University](https://connect.biorxiv.org/group/content/37) * [Northeastern University](https://connect.biorxiv.org/group/content/54) * [Oregon Health & Sciences University](https://connect.biorxiv.org/group/content/22) * [RNA Therapeutics Institute at UMass Chan Med School](https://connect.biorxiv.org/relate/content/243) * [Rosetta Commons](https://connect.biorxiv.org/relate/content/191) * [Rutgers University](https://connect.biorxiv.org/group/content/31) * [SeroNet](https://connect.biorxiv.org/relate/content/192) * [Simons Foundation Autism Research Initiative (SFARI)](https://connect.biorxiv.org/relate/content/74) * [Society for Molecular Biology and Evolution #SMBE2016](https://connect.biorxiv.org/relate/content/29) * [Somatic Cell Genome Editing Program](https://connect.biorxiv.org/relate/content/167) * [Somatic Mosaicism across the Human Tissues Network](https://connect.biorxiv.org/relate/content/222) * [SPARC](https://connect.biorxiv.org/relate/content/187) * [Stowers Institute for Medical Research](https://connect.biorxiv.org/group/content/3) * [Stockholm University](https://connect.biorxiv.org/group/content/14) * [Tel Aviv University](https://connect.biorxiv.org/group/content/8) * [The Michael J. Fox Foundation](https://connect.biorxiv.org/relate/content/207) * [The Rockefeller University](https://connect.biorxiv.org/group/content/2) * [The Sainsbury Laboratory](https://connect.biorxiv.org/relate/content/98) * [The Whitehead Institute](https://connect.biorxiv.org/relate/content/212) * [University of Connecticut Health Center](https://connect.biorxiv.org/group/content/16) * [University of California, Berkeley](https://connect.biorxiv.org/group/content/13) * [University of California, San Diego](https://connect.biorxiv.org/group/content/41) * [University of California, San Francisco](https://connect.biorxiv.org/group/content/10) * [University of Chicago](https://connect.biorxiv.org/group/content/42) * [University of Geneva](https://connect.biorxiv.org/group/content/26) * [University of Guelph](https://connect.biorxiv.org/group/content/23) * [University of Hong Kong](https://connect.biorxiv.org/group/content/29) * [University of Illinois Chicago](https://connect.biorxiv.org/group/content/43) * [University of Iowa](https://connect.biorxiv.org/group/content/24) * [University of Kansas](https://connect.biorxiv.org/group/content/33) * [University of Massachusetts Chan Medical School](https://connect.biorxiv.org/group/content/44) * [University of New South Wales](https://connect.biorxiv.org/group/content/25) * [University of Ottawa](https://connect.biorxiv.org/group/content/35) * [University of Sydney](https://connect.biorxiv.org/group/content/50) * [Vanderbilt University](https://connect.biorxiv.org/group/content/30) * [Vienna BioCenter](https://connect.biorxiv.org/relate/content/186) * [Washington University in St. Louis](https://connect.biorxiv.org/group/content/11) * [Weizmann Institute of Science](https://connect.biorxiv.org/group/content/15) * [Yale University](https://connect.biorxiv.org/group/content/53) Search for this keyword [Advanced Search](https://www.biorxiv.org/search) New Results Follow this preprint # A Standalone PD-1 Chimeric Switch Receptor T-Cell Platform Expands the Therapeutic Window of PD-L1 Targeting in Solid Tumors Yan Luo, Shaohua Guo, Yaqing Qie, Binyan Zhao, Maria Jose Ulloa-Navas, Mieu Brooks, Vanessa Jones, [ View ORCID Profile](http://orcid.org/0000-0003-2075-7919)Tanya Hundal, Julio C Chavez, Yanyan Lou, [ View ORCID Profile](http://orcid.org/0000-0002-1129-744X)Loic Pierre Deleyrolle, Vamsidhar Velcheti, James W Jakub, Roxana Dronca, Mohamed A Kharfan-Dabaja, Alfredo Quinones-Hinojosa, Hong Qin doi: https://doi.org/10.64898/2026.11.05.764663 This article is a preprint and has not been certified by peer review [[what does this mean?](https://www.biorxiv.org/about/FAQ#unrefereed)]. Yan Luo 1 Regenerative Immunotherapy & CAR-T Translational Research Program, Department of Cancer Biology, Mayo Clinic Jacksonville, FL, USA.; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Yan%2BLuo%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Luo%20Y&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AYan%2BLuo%2B) Shaohua Guo 2 Regenerative Immunotherapy & CAR-T Translational Research Program, Mayo Clinic Jacksonville, FL, USA; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Shaohua%2BGuo%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Guo%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AShaohua%2BGuo%2B) Yaqing Qie 2 Regenerative Immunotherapy & CAR-T Translational Research Program, Mayo Clinic Jacksonville, FL, USA; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Yaqing%2BQie%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Qie%20Y&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AYaqing%2BQie%2B) Binyan Zhao 2 Regenerative Immunotherapy & CAR-T Translational Research Program, Mayo Clinic Jacksonville, FL, USA; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Binyan%2BZhao%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Zhao%20B&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3ABinyan%2BZhao%2B) Maria Jose Ulloa-Navas 3 The Neurosurgery Department, Mayo Clinic Jacksonville, FL, USA; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Maria%2BJose%2BUlloa-Navas%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Ulloa-Navas%20MJ&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AMaria%2BJose%2BUlloa-Navas%2B) Mieu Brooks 3 The Neurosurgery Department, Mayo Clinic Jacksonville, FL, USA; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Mieu%2BBrooks%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Brooks%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AMieu%2BBrooks%2B) Vanessa Jones 3 The Neurosurgery Department, Mayo Clinic Jacksonville, FL, USA; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Vanessa%2BJones%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Jones%20V&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AVanessa%2BJones%2B) Tanya Hundal 4 Regenerative Immunotherapy & CAR-T Translational Research Program, Department of Cancer Biology, Mayo Clinic in Florida; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Tanya%2BHundal%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Hundal%20T&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3ATanya%2BHundal%2B) * [ORCID record for Tanya Hundal](http://orcid.org/0000-0003-2075-7919 "Open in new tab") Julio C Chavez 5 Division of Hematology and Medical Oncology, Department of Internal Medicine, Mayo Clinic Jacksonville, FL, USA; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Julio%2BC%2BChavez%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Chavez%20JC&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AJulio%2BC%2BChavez%2B) Yanyan Lou 5 Division of Hematology and Medical Oncology, Department of Internal Medicine, Mayo Clinic Jacksonville, FL, USA; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Yanyan%2BLou%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Lou%20Y&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AYanyan%2BLou%2B) Loic Pierre Deleyrolle 6 Department of Molecular Medicine, Mayo Clinic, MN, USA; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Loic%2BPierre%2BDeleyrolle%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Deleyrolle%20LP&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3ALoic%2BPierre%2BDeleyrolle%2B) * [ORCID record for Loic Pierre Deleyrolle](http://orcid.org/0000-0002-1129-744X "Open in new tab") Vamsidhar Velcheti 5 Division of Hematology and Medical Oncology, Department of Internal Medicine, Mayo Clinic Jacksonville, FL, USA; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Vamsidhar%2BVelcheti%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Velcheti%20V&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AVamsidhar%2BVelcheti%2B) James W Jakub 7 Department of Surgery, Mayo Clinic, Jacksonville, FL, USA; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=James%2BW%2BJakub%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Jakub%20JW&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AJames%2BW%2BJakub%2B) Roxana Dronca 5 Division of Hematology and Medical Oncology, Department of Internal Medicine, Mayo Clinic Jacksonville, FL, USA; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Roxana%2BDronca%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Dronca%20R&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3ARoxana%2BDronca%2B) Mohamed A Kharfan-Dabaja 5 Division of Hematology and Medical Oncology, Department of Internal Medicine, Mayo Clinic Jacksonville, FL, USA; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Mohamed%2BA%2BKharfan-Dabaja%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Kharfan-Dabaja%20MA&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AMohamed%2BA%2BKharfan-Dabaja%2B) Alfredo Quinones-Hinojosa 3 The Neurosurgery Department, Mayo Clinic Jacksonville, FL, USA; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Alfredo%2BQuinones-Hinojosa%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Quinones-Hinojosa%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AAlfredo%2BQuinones-Hinojosa%2B) Hong Qin 8 Regenerative Immunotherapy & CAR-T Translational Research Program, Department of Cancer Biology, Division of Hematology and Medical Oncology, Department of Internal Medicine, Department of Immunology, Mayo Clinic, MN, USA * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Hong%2BQin%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Qin%20H&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AHong%2BQin%2B) * For correspondence: qin.hong@mayo.edu * [Abstract](https://www.biorxiv.org/content/10.64898/2026.11.05.764663v1)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_art/node:5946211/1) * [Info/History](https://www.biorxiv.org/content/10.64898/2026.11.05.764663v1.article-info)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_info/node:5946211/1) * [Metrics](https://www.biorxiv.org/content/10.64898/2026.11.05.764663v1.article-metrics)[](https://www.biorxiv.org/panels_ajax_tab/article_tab_metrics/node:5946211/1) * [Supplementary material](https://www.biorxiv.org/content/10.64898/2026.11.05.764663v1.supplementary-material)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_data/node:5946211/1) * [ Preview PDF](https://www.biorxiv.org/content/10.64898/2026.11.05.764663v1.full.pdf+html)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:5946211/1) ![Loading](https://www.biorxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Programmed death-ligand 1 (PD-L1) is a promising therapeutic target owing to its broad expression on tumor cells and immunosuppressive myeloid cells within the
## Related Clinical Research

- [U.S. POINTER: Structured lifestyle program slows brain aging and cardiometabolic risk over 24 mont](https://medichelpline.com/clinical-feed/medical-news-today-0-combining-physical-mental-and-social-habits-slows-brain-aging-in-2-year-trial.md)
- [fMRI-based ARC tool differentiates SuperAgers from Alzheimer’s with strong AUC](https://medichelpline.com/clinical-feed/medical-news-today-2-new-brain-imaging-tool-distinguishes-between-alzheimer-s-disease-and-superagers.md)
- [Mesh Variability Causes Percent-Level Differences in Temporal Interference Stimulation Simulations](https://medichelpline.com/clinical-feed/biorxiv-9-independent-mesh-realizations-introduce-percent-level-variability-in-temporal.md)
- [FDA approves Roche’s Wilserdly (giredestrant) for ESR1-mutant HR-positive, HER2-negative breast ca](https://medichelpline.com/clinical-feed/stat-news-0-stat-fda-approves-new-breast-cancer-drug-providing-new-option-for-some-patients.md)
- [EHR Phenotype Choice Alters Outcomes: Three Invasive Breast Cancer Definitions Compared in TriNetX](https://medichelpline.com/clinical-feed/plos-one-6-electronic-health-record-phenotype-choice-and-real-world-outcome-estimates-a.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.